Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, with additional offices in Beijing, Suzhou, and Hong Kong. Founded in 2006, the firm specializes in investing in early to growth-stage companies across various sectors, including healthcare, information technology, consumer products, media, and clean technology. Qiming has established itself as a leading investment firm in China, managing multiple funds with over $1 billion in assets. The firm focuses on supporting innovative entrepreneurs and companies that demonstrate high growth potential, particularly in the technology and healthcare landscapes. Through its strategic investments, Qiming aims to foster the development of new business models and technologies, contributing to the dynamic entrepreneurial ecosystem in China.

Zhang Ao

Executive Director

Artavazd Arumov Ph.D

Principal

Ryan Baker

CFO

Cyrus Chan

Associate

Kan Chen

Partner

Liwen Chen

Associate

Nan Chen

Principal

David Chu

Partner

Isaac Ciechanover

Partner

Phil DiGiacomo

Principal

Anna French

Managing Partner

Yuxin Fu

Associate

Jinda Gao

Principal

Ye Guantai

Partner

Robert Headley

Partner

Maykin Ho Ph.D

Venture Partner

William Hu

Managing Partner

Duane Kuang

Co-Founder and Managing Partner

Nisa Leung

Managing Partner

Lisa Li

Investor

Dingzheng Li

Vice President

Jing Liu

Associate

Chang Liu

Associate

Bin Liu

Associate

Biao Lu

Associate

Shuo Mao

Principal

Will Mcconnell

Principal

Mark Mcdade

Co-Founder and Managing Partner

Gary Rieschel

Co-Founder and Managing Partner

Motao Sun

Associate

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Bonnie Wang

Principal

Rachel Wang

Venture Partner

Xin Wang

Investor

James Wang

Venture Partner

Gillian Xu

RMB funds CFO

Kuantai Yeh

Partner

Peter (Ming) Yin

Principal, Cleantech

Janet Yu Ph.D

Partner

Liang Yuyu

Managing Partner

Oscar Zhang

Principal

Yafeng Zhou

Associate

Alex Zhou

Managing Partner

Zhiyuan Zhou

Investor

Zhifeng Zhou

Managing Partner

Yiqing Zhu

Associate

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Phillip DiGiacomo Ph.D

Principal

826 past transactions

NFTGO

Convertible Note in 2023
NFTGo is a data aggregation platform focused on non-fungible tokens (NFTs), providing users with comprehensive information about the NFT market. The platform enables users to track and analyze NFT drops, rankings, and whale activity through its advanced search engine and market data tools. Utilizing a proprietary blockchain data collection engine, NFTGo gathers and processes the latest on-chain transaction data, presenting it in an accessible format for users to understand NFT trends and market dynamics. This facilitates NFT project stakeholders in accurately identifying potential customers while helping users navigate the evolving NFT landscape.

Joes Future Food

Series A in 2023
Developer of artificial meat. The company develops artificial meat and cultured alternative protein products at the cellular level, committing to creating a new solution for future food supply.

Bioyond Tech

Series A in 2023
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Deepway

Series A in 2023
Deepway is a manufacturer of smart vehicles focused on providing intelligent driving solutions for the truck freight market. The company specializes in heavy-duty trucks characterized by low wind resistance bodies and advanced intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to benefit from enhanced efficiency through smart freight systems, ultimately improving transportation and logistics operations.

Hochuen Medical

Series B in 2023
Hochuen Medical, founded in 2015 by Dr. Robin Liu and Eric Zeng, specializes in contract development and manufacturing, focusing on microfluidic chips and biomedical consumables. The company leverages the extensive management experience of its founders, who have over 20 years in the fields of in vitro diagnostics (IVD), microfluidics, and electronics manufacturing. Hochuen Medical produces a range of in vitro diagnostic products, including microfluidic biochips, disposable consumables for IVD, point-of-care testing kits, life science research consumables, gene sequencing chips, and detection cards for animal, plant, and food safety testing. The company is committed to providing clients with high-quality, end-to-end contract manufacturing solutions, drawing on its expertise in research and production management.

Yike Polymers

Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.

Soda Health

Series A in 2022
Soda Health is a healthcare technology company dedicated to addressing health inequities and promoting a healthier America. The company offers a technology platform designed to help individuals identify, access, and pay for essential resources that support their health and well-being. By providing personalized benefits and streamlining the reimbursement process, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, making healthcare more accessible and affordable.

CSR Biotech

Seed Round in 2022
Guangzhou Chaoshiji Biotechnology Co., Ltd. (Chaoshiji Technologies) is a high-tech company specializing in the creation and deployment of super-resolution imaging devices for living cells. R&D, production, sales, after-sales, and technical output services for various types of super-resolution optical microscopes are the primary activities. Among the services offered are customized cell sample generation, customized cell sample high-throughput detection, customized cell sample imaging studies, and customized image post-processing and quantitative analysis.

Deepway

Series A in 2022
Deepway is a manufacturer of smart vehicles focused on providing intelligent driving solutions for the truck freight market. The company specializes in heavy-duty trucks characterized by low wind resistance bodies and advanced intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to benefit from enhanced efficiency through smart freight systems, ultimately improving transportation and logistics operations.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

CIX Technology

Seed Round in 2022
CIX Technology develops high-performance, next-generation intelligent computing solutions.

Gaugene

Series B in 2022
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.

Biotree

Series A in 2022
Shanghai Biotree Biotech Co., Ltd. specializes in the development and application of life science research technologies. Founded in 2013, the company is based in Shanghai, China, and focuses on sample testing, big data analysis, and technical product development within the life sciences sector. It offers a range of professional services tailored to universities, research institutes, hospitals, and enterprises. Biotree is particularly noted for its expertise in metabolomics, providing early detection and analysis services, as well as consulting related to mass spectrometry and metabolic testing. The company has a strong portfolio of patents in metabolomics and continues to innovate in product development and technology within this field. Since its inception, Biotree has demonstrated consistent growth and profitability, establishing itself as a key player in the domestic metabolomics detection and analysis market.

Ark Biosciences

Series D in 2022
Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.

LaNova Medicines

Series B in 2022
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Boulder Care

Series B in 2022
Boulder Care, Inc. is a telemedicine-based platform focused on treating opioid addiction through a combination of medication and peer support. Founded in 2017 and located in Portland, Oregon, the company provides comprehensive services that include patient support, medication management, and psychosocial services. By leveraging digital health technology, Boulder Care aims to improve access to effective treatment for individuals struggling with opioid use, enhancing the experience for both patients and their care teams. The organization serves a diverse clientele, including patients, providers, and various health organizations, contributing to the advancement of the behavioral health industry.

InSilico Medicine

Series D in 2022
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Point One

Series B in 2022
Building the next-gen consumer products!

BUD

Series B in 2022
Founded in 2019 by former Snap engineers, Risa Feng and Shawn Lin, Singapore-headquartered BUD is a leading global metaverse UGC platform encouraging users to create and share 3D interactive experiences with its easy-to-use creation tools. Since its global launch in November 2021, BUD skyrocketed to the list of top 10 social apps in more than 38 countries around the world including North America, Southeast Asia and South America. Millions of 3D content has been created and traded on the platform. BUD has become a digital social hub where millions of people come to create, play and hangout.

Yike Polymers

Series B in 2022
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.

AskGene Pharma

Series A in 2022
AskGene Pharma is a biotechnology firm. It is developing novel cytokine prodrugs to address critical unmet medical needs in oncology and autoimmune disease. It is unlocking the full therapeutic potential of cytokine molecules with their innovative smart kine prodrug platform. It overcomes a number of significant challenges, providing a clear pathway to a range of next-generation cytokine therapies. They provide safer and better medicines for saving patients’ lives. They are equipped with the most advanced R&D facilities.

Ashermed

Series B in 2022
Developer of contract research organization (CRO) platform for medical companies. The company focuses on the integration of CRO with Internet technology, big data, artificial intelligence and other advanced technologies, enabling medical companies to shorten the drug development cycle, improve the quality of clinical data and reduce research and development costs.

Rhino Health

Venture Round in 2022
Developer of a federated learning and edge-computing platform designed to allow artificial intelligence (AI) /data-science developers to collaborate without sharing data or compromising data privacy. The company's platform distributed computing technologies AI models can quickly and continuously improve by learning from each new dataset and applying those learnings to the next, without requiring costly and risky data transfers, helping users to accelerate the creation and training of more accurate models that work consistently across different patient populations.

CIX Technology

Angel Round in 2022
CIX Technology develops high-performance, next-generation intelligent computing solutions.

Onechip Bioelectronics

Series B in 2022
Zhangjiagang Onechip Bio-Technology Co.,Ltd. develops and manufactures new generations of biochemical sensor chips and nanomaterials for various applications. It offers pH chip, such as nano-electrodes; biochips; and nanometer materials, including oil absorption and sustained release products and battery protection products. The company’s products are based on the nanoscale electronic biochemical sensors and nanomaterial technologies. It sells its products online. Zhangjiagang Onechip Bio-Technology Co.,Ltd. was founded in 2014 and is based in Zhangjiagang, China.

Houmo.AI

Series A in 2022
Houmo.AI is a semiconductor company that develops an integrated circuit storage technology for AI computing. The company aims to use disruptive technologies to create AI chips with a "ten-fold effect", to meet the huge computing power demand in the era of true artificial intelligence, and to use unlimited computing power to change the world. Houmo.AI was founded by Dr. Wu Qiang in 2020.

LTZ Therapeutics

Seed Round in 2022
LTZ Therapeutics is engaged in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. The company employs reverse translational science and tumor biology, integrating these approaches with machine learning to advance its immunotherapy solutions. This strategy enables LTZ Therapeutics to create novel cancer treatments that address significant unmet clinical needs, ultimately striving to improve patient outcomes in the field of oncology.

Clique

Seed Round in 2022
Clique is building identity oracles that connect web2 user behavior data with web3 applications. We leverage advanced cryptographic tech like ZKP, TEE, and MPC to develop modular solutions with customizable privacy assumptions. Our main products are designed to help protocols, creators, and brands identify high-value users/fans, perform Sybil-resistant checks and distribute incentives accordingly. We already have 100+ partners across major L1/L2s, exchanges, marketplaces, NFT/GameFi/SocialFi projects, etc. We were previously incubated by Alliance DAO and Stanford Blockchain Accelerator and raised millions in funding from renowned VCs like GGV, Qiming, Infinity Ventures Crypto, Sky9, SevenX, Smrti Lab, etc. Our team has a strong technical background and comes from prestigious institutions like Duke, Cambridge, NUS, Tsinghua, Citi bank, Brevan Howard, etc. Our advisors include top cryptography researchers, past founders of established media companies, as well as famous Hollywood directors and writers.

ACXEL

Seed Round in 2022
ACXEL Tech develops large area electronics have given us flat panel displays and flexible, wearable devices. ACXEL takes these ‘active’ pixels and puts them to work transporting liquid droplets – precisely and at amazing speed. Millions of pixels are transformed into tiny engines moving samples around via a high throughput, low cost and programmable platform, offering a wide range of possibilities in chemistry, biology and medtech.

MeetFuture China

Series B in 2022
MeetFuture China is a technology-driven company that supplies automated transmission systems for the pan-semiconductor industry. It provides automation solutions for leading companies in the semiconductor field since 2016 and provided a highly advantageous overall for industrial upgrading and development with independent and controllable core technologies.

Medilink Therapeutics

Series B in 2022
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

BlockVision

Seed Round in 2022
BlockVision operates as a high-availability indexing network that facilitates complex queries and data storage across various blockchains, including Ethereum, BNB Chain, Arbitrum, and Optimism. The company has developed an enhanced application programming interface (API) platform aimed at developers, streamlining the process of building and executing blockchain queries. By offering a series of user-friendly APIs, BlockVision enables clients to efficiently manage data interactions within the evolving landscape of web 3.0, thereby improving overall user experience.

GluBio Therapeutics

Series A in 2022
GluBio Pharmaceutical focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Prime Lifescience

Seed Round in 2022
Prime Lifescience is a developer of a big data platform tailored for the life sciences sector. The company focuses on creating a health lifecycle big data collaboration network through innovative digital technologies and the application of artificial intelligence. Prime Lifescience offers a range of services, including a digital smart health community, a digital intelligent clinical research accelerator, and a live big data platform. These offerings aim to enhance digital clinical research and foster a comprehensive medical solutions framework within the healthcare industry, leveraging extensive data to improve health outcomes.

Wowjoy Technology

Series A in 2022
Wowjoy Technology develops a platform to provide data-driven medical services. The firm is headquartered in Hangzhou, China.

NFTGO

Seed Round in 2022
NFTGo is a data aggregation platform focused on non-fungible tokens (NFTs), providing users with comprehensive information about the NFT market. The platform enables users to track and analyze NFT drops, rankings, and whale activity through its advanced search engine and market data tools. Utilizing a proprietary blockchain data collection engine, NFTGo gathers and processes the latest on-chain transaction data, presenting it in an accessible format for users to understand NFT trends and market dynamics. This facilitates NFT project stakeholders in accurately identifying potential customers while helping users navigate the evolving NFT landscape.

SilaGene, Inc.

Series A in 2022
SilaGene, Inc. is a biotechnology company based in Hillsborough, New Jersey, founded in 2008. The company specializes in the development of U1 adaptors that hold therapeutic potential for various diseases, particularly in the treatment of different types of cancers. Its innovative technology serves as a gene silencing tool, which enhances the research of gene function in both cell cultures and in vivo settings. By addressing the limitations of existing gene silencing technologies, SilaGene aims to provide effective treatment options for patients.

Deep View Technology

Series B in 2022
Beijing Deep View Technology Co., Ltd. engaged in research on 3D computer vision algorithm. The company is based in Beijing, China.

Axera

Series A in 2022
Developer of an artificial intelligence chip designed to focus on the visual field. The company's chip offers good performance with low power consumption, low-latency, and high-integration architecture system, enabling clients to have real-time video analysis on the terminal, good quality video shooting, and real-time multi-camera integration with low cost.

Eigencomm

Series C in 2022
Eigencomm is dedicated to the development and sales of cellular IoT chips.

Zhenge Biotech

Series C in 2022
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

MKSEMI

Series A in 2022
Provider of high precision location technology IC and solutions. The company focuses on developing high performance, low-power, and highly integrated IC and provides solutions in smartphones, wearables, digital health, smart home and general IoT applications.

CureGenetics

Series B in 2022
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Korro Bio

Series B in 2022
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

Tungee

Series B in 2021
Guangzhou Tungee Technology Co., Ltd., established in 2016 and headquartered in Panyu, China, specializes in providing intelligent sales solutions through its software as a service (SaaS) platform. The company offers a comprehensive suite of tools for enterprises, including leads mining, business opportunity engagement, customer relationship management, and order analysis, all powered by advanced technologies such as artificial intelligence, natural language processing, and machine learning algorithms. Tungee has built an extensive database covering 100 million enterprises, enabling its clients to efficiently identify, contact, and manage customers. By improving the accuracy of sales leads and reducing customer acquisition costs, Tungee enhances sales efficiency and performance. The company has served over 3,000 enterprise clients, including notable names like Alibaba and China Mobile, establishing itself as a leader in the intelligent sales sector in China.

Popop World

Seed Round in 2021
PoPop World is a leisure playground with 20+ mini games.

InfStones

Series B in 2021
Infinity Stones is a Silicon Valley-based company that provides cloud management services and security solutions for blockchains. They are blockchain infrastructure architects with proven track records in the industry. Their team is composed of tech leads, management experts, and financial professionals from tech giants like Google, Oracle, and Intel. Infinity Stones is currently hosting nodes for high net worth individuals, institutional investors, foundations, and universities and research institutions. They make sure every investment with us is secure, and investors can expect returns with consistency. It was founded in 2018 and is headquartered in Palo Alto, California.

DPTechnology

Series B in 2021
DPTechnology, founded in 2018 and based in Beijing, China, specializes in micro-scale industrial design through advanced molecular simulation technology. The company has developed a platform that integrates artificial intelligence with molecular simulation algorithms, aiming to enhance industrial and medical research. By providing users with innovative scientific tools, DPTechnology promotes efficiency and creativity in exploring complex research challenges, thereby establishing a new paradigm in both industrial research and clinical applications.

Sinogen Biopharma

Venture Round in 2021
Sinogen Biopharma is a biotechnology company dedicated to connecting China's innovative drug development with the pharmaceutical market in the United States. The company specializes in the licensing and development of bacterial carrier-based biological anti-tumor drugs aimed at treating malignant tumors, particularly in the area of metastatic tumors and rare diseases. By focusing on the creation of innovative anti-cancer therapies, Sinogen Biopharma seeks to address the needs of both domestic and international pharmaceutical markets.

Wholee

Series B in 2021
Wholee is a member-only zero-markup store.

Xinchuangyuan Semiconductor

Series A in 2021
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.

Frontis

Seed Round in 2021
Frontis focuses on using cutting-edge AI technology to enable enterprise customers in the whole process of product lifecycle management with full automation for product design, supply chain analysis, consumer insights, sales forecasting, and user experience enhancement. The company is headquartered in Beijing, China.

SUPERHEXA

Series A in 2021
Superhexa is a hardware company based in Beijing, founded on October 15, 2020, by Xia Yongfeng. It specializes in the development of personal consumer electronics, aiming to integrate technology seamlessly into everyday life. By focusing on innovation, Superhexa seeks to enhance the user experience and adapt to the evolving needs of consumers.

Clinflash Heathcare Technology

Venture Round in 2021
Clinflash is a leading provider of cloud-based solution and relevant professional service in filed of clinical development in China. Clinflash aims to help pharmaceutical companies improve R&D effectiveness and efficiency through providing first class IT solution and professional service.

Gemsouls

Series A in 2021
Gemsouls is an AI technology that powers virtual characters and their interactions with the real world. Headquarterd in Shanghai.

Yunji Technology

Venture Round in 2021
Yunji Technology is a Chinese robot company that builds a commercial service robot capable of delivering goods.

Allorion Therapeutics

Series A in 2021
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

Cornerstone Robotics

Series B in 2021
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.

Tripod Preclinical Research

Venture Round in 2021
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

Platelet BioGenesis

Series B in 2021
Platelet BioGenesis is a biotechnology company focused on producing donor-independent human platelets from pluripotent stem cells for clinical use. Founded in 2014 and based in Cambridge, Massachusetts, the company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. Platelet BioGenesis distributes these bioreactor-produced platelets to hospitals and blood banks, aiming to provide a reliable source of platelets for patients worldwide. By specializing in the fields of platelets and drug discovery, the company is addressing critical needs in the medical community related to blood supply and treatment options.

Genedit

Angel Round in 2021
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.

Shanzhen

Series D in 2021
Shanzhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups and personalized health management plans, alongside insurance options. Additionally, Shanzhen offers a range of medical examination services and data finance products aimed at tackling the challenges posed by an aging population and the rising incidence of chronic diseases. By prioritizing the well-being of elderly patients, Shanzhen aims to enhance their quality of life, enabling them to lead happier and healthier lives.

Genlight

Series B in 2021
Genlight is a company based in Hangzhou, China, that specializes in developing advanced treatment solutions for epilepsy and other neurological disorders. The organization focuses on innovative technologies in the field of brain science and neurosurgery, creating laser medical equipment designed to improve patient outcomes. Genlight's offerings include brain-computer control technology, deep brain nerve stimulation with full-cranial implantation, brain computer chips, and a minimally invasive surgery system guided by magnetic resonance. These high-tech solutions aim to provide patients with effective and cutting-edge surgical options for neurological conditions.

Atom Semiconductor

Venture Round in 2021
Atom Semiconductor is a scientific and technological enterprise focusing on digital sensor design. Atom Semiconductor was founded in 2020.

Okeanos Technology

Series B in 2021
Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company's primary offerings include modified nucleotides, unnatural amino acids, heterocycles, and fluorescent and labeling reagents. Okeanos supplies these products to leading pharmaceutical companies, earning a strong reputation for quality and reliability. The firm focuses on providing clients with a diverse range of chemical compounds and biochemical reagents, particularly in the realms of sequencing and synthetic biology.

Bioyond Tech

Seed Round in 2021
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Zeen Health

Venture Round in 2021
Zeen Health is a digital therapeutics company that provides mental health services. Zeen Health was founded in 2019 and was headquartered in Shenzhen, China.

Supermag

Series A in 2021
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.

Cubenergy Technology

Series A in 2021
Shenzhen Cubenergy Technology Co., Ltd. is an energy technology company established in 2015 and based in Shenzhen, China. The company specializes in providing comprehensive energy data operation services and integrating distributed energy storage systems. Cubenergy Technology develops energy management and storage systems that utilize data analysis to optimize system performance and maintain efficiency. By focusing on these advanced technologies, the company aims to enhance energy management solutions for its users.

Structure Therapeutics

Series B in 2021
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.

Clounix

Seed Round in 2021
Developer of application-specific integrated circuit (ASIC) designed for cloud networking. The company develops ASIC used for high speed packet switching, improving cloud networking technology.

Clounix

Seed Round in 2021
Developer of application-specific integrated circuit (ASIC) designed for cloud networking. The company develops ASIC used for high speed packet switching, improving cloud networking technology.

Qingflow

Series B in 2021
Qingflow is a software-as-a-service platform that enables users to create management systems. Qingflow is located in Minhang District, Shanghai.

Brise Pharma

Angel Round in 2021
Brise Pharma operates in the scientific research and technical service industry.

Jasper Therapeutics

Post in 2021
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.

Sunyur

Series B in 2021
Sunyur is an e-purchase solution provider.

Ventyx Biosciences

Series B in 2021
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Genevide

Angel Round in 2021
Genevide is a biotech company founded in 2019 and based in Suzhou, Jiangsu, China, focusing on gene research and development. The company has developed a molecular enzyme cycle screening platform designed to address challenges in nucleic acid detection. Its key technologies include enzyme-mediated one-step sample processing and enzyme-mediated double exponential amplification, which facilitate efficient nucleic acid detection for researchers. Genevide aims to provide innovative solutions that make nucleic acid detection more accessible and effective.

XellSmart

Seed Round in 2021
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.

Alamar Biosciences

Series B in 2021
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

BUD

Series A in 2021
Founded in 2019 by former Snap engineers, Risa Feng and Shawn Lin, Singapore-headquartered BUD is a leading global metaverse UGC platform encouraging users to create and share 3D interactive experiences with its easy-to-use creation tools. Since its global launch in November 2021, BUD skyrocketed to the list of top 10 social apps in more than 38 countries around the world including North America, Southeast Asia and South America. Millions of 3D content has been created and traded on the platform. BUD has become a digital social hub where millions of people come to create, play and hangout.

Wowjoy Technology

Series A in 2021
Wowjoy Technology develops a platform to provide data-driven medical services. The firm is headquartered in Hangzhou, China.

moodytiger

Series B in 2021
Moody Tiger is an international activewear brand established in 2018, focusing on functional and fashionable athleisurewear for children aged 4 to 14 years. The company specializes in developing high-tech fabrics that ensure comfort and quality, catering to the needs of active children. By combining style with practicality, Moody Tiger aims to provide a range of fashion-forward activewear options that appeal to both children and their parents.

Pluslife

Series A in 2021
PlusLife Biotech is devoted to developing revolutionary molecular diagnostic tools and gene treatment programs employing a new generation of gene technology. Founded in 2017 and is based in Guangzhou, China.

V Light

Series A in 2021
V Light is an interest social app.

Gyenno Science

Series B in 2021
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.

Sanegene Bio

Series A in 2021
Sanegene Bio is currently operating in stealth mode.

Lingyi Zhihui

Series B in 2021
Zuoshouyisheng's AI ​​doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. Zuoshouyisheng mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.

Houmo.AI

Seed Round in 2021
Houmo.AI is a semiconductor company that develops an integrated circuit storage technology for AI computing. The company aims to use disruptive technologies to create AI chips with a "ten-fold effect", to meet the huge computing power demand in the era of true artificial intelligence, and to use unlimited computing power to change the world. Houmo.AI was founded by Dr. Wu Qiang in 2020.

InfStones

Series A in 2021
Infinity Stones is a Silicon Valley-based company that provides cloud management services and security solutions for blockchains. They are blockchain infrastructure architects with proven track records in the industry. Their team is composed of tech leads, management experts, and financial professionals from tech giants like Google, Oracle, and Intel. Infinity Stones is currently hosting nodes for high net worth individuals, institutional investors, foundations, and universities and research institutions. They make sure every investment with us is secure, and investors can expect returns with consistency. It was founded in 2018 and is headquartered in Palo Alto, California.

Abogen Biosciences

Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Soda Health

Seed Round in 2021
Soda Health is a healthcare technology company dedicated to addressing health inequities and promoting a healthier America. The company offers a technology platform designed to help individuals identify, access, and pay for essential resources that support their health and well-being. By providing personalized benefits and streamlining the reimbursement process, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, making healthcare more accessible and affordable.

Berry Oncology

Series B in 2021
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

Allorion Therapeutics

Series A in 2021
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

Yunqi

Seed Round in 2021
Yunqi is an efficient cloud e-commerce business platform that distributes software products and technical services. Yunqi provides ways to do business in different sales channels. It also provides systems and services to help businesses do business in various modes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.